Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

Y0001416

Betamethasone dipropionate for peak identification

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
Betamethasone 17,21-dipropionate, 9α-Fluoro-16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 17,21-dipropionate
Empirical Formula (Hill Notation):
C28H37FO7
CAS Number:
5593-20-4
Molecular Weight:
504.59
MDL number:
MFCD00133140
UNSPSC Code:
41116107
PubChem Substance ID:
329831413
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

betamethasone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[H][C@@]12C[C@H](C)[C@](OC(=O)CCl)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)C3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

1S/C27H34ClFO7/c1-5-22(33)35-14-21(32)27(36-23(34)13-28)15(2)10-19-18-7-6-16-11-17(30)8-9-24(16,3)26(18,29)20(31)12-25(19,27)4/h8-9,11,15,18-20,31H,5-7,10,12-14H2,1-4H3/t15-,18-,19-,20-,24-,25-,26?,27-/m0/s1

InChI key

UOCNBCVPZWLUKX-HOBFILNXSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Betamethasone dipropionate for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Betamethasone 17,21-dipropionate is a glucocorticoid with anti-inflammatory and immunosuppressive activity.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1067001

Betamethasone acetate, United States Pharmacopeia (USP) Reference Standard

1067704

Betamethasone dipropionate, United States Pharmacopeia (USP) Reference Standard

1069007

Betamethasone valerate, United States Pharmacopeia (USP) Reference Standard

1068004

Betamethasone sodium phosphate, United States Pharmacopeia (USP) Reference Standard

B1055000

Betamethasone 21-valerate, European Pharmacopoeia (EP) Reference Standard

B1054000

Betamethasone 17-valerate, European Pharmacopoeia (EP) Reference Standard

B1000000

Betamethasone, European Pharmacopoeia (EP) Reference Standard

B1030000

Betamethasone acetate, European Pharmacopoeia (EP) Reference Standard

B1040000

Betamethasone dipropionate, European Pharmacopoeia (EP) Reference Standard

B1045000

Betamethasone sodium phosphate, European Pharmacopoeia (EP) Reference Standard

Y0001065

Betamethasone valerate impurity mixture, European Pharmacopoeia (EP) Reference Standard

Y0001027

Betamethasone valerate for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR1398

Betamethasone, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1399

Betamethasone Dipropionate, Pharmaceutical Secondary Standard; Certified Reference Material

1066009

Betamethasone, United States Pharmacopeia (USP) Reference Standard

1069018

Betamethasone Valerate Related Compound A, United States Pharmacopeia (USP) Reference Standard

1067307

Betamethasone benzoate, United States Pharmacopeia (USP) Reference Standard

PHR1779

Betamethasone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1780

Betamethasone Valerate, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001925

Betamethasone dipropionate for system suitability A, European Pharmacopoeia (EP) Reference Standard

BP041

Betamethasone sodium phosphate, British Pharmacopoeia (BP) Reference Standard

BP575

Betamethasone, British Pharmacopoeia (BP) Reference Standard

BP043

Betamethasone 21-valerate, British Pharmacopoeia (BP) Reference Standard

BP042

Betamethasone valerate, British Pharmacopoeia (BP) Reference Standard

1067045

Betamethasone Acetate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1067726

Betamethasone Dipropionate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1067737

Betamethasone Dipropionate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1067760

Betamethasone Dipropionate Related Compound F , United States Pharmacopeia (USP) Reference Standard

1067781

Betamethasone dipropionate Related Compound H, United States Pharmacopeia (USP) Reference Standard

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H360FD,H373

Hazard Classifications

Repr. 1B - STOT RE 2

Target Organs

Liver,Kidney,Endocrine system

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Andrew G Affleck et al.
Current medical research and opinion, 27(1), 269-284 (2010-12-15)
To compare the cost effectiveness of the two-compound formulation (TCF) calcipotriol plus betamethasone dipropionate gel used first-, second- or third-line to standard topical treatments for moderately severe scalp psoriasis from a Scottish NHS perspective. Treatment pathways for scalp psoriasis patients
Peter van de Kerkhof et al.
Current medical research and opinion, 27(1), 225-238 (2010-12-15)
The efficacy of the two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate applied once daily in psoriasis has been demonstrated in phase III trials but no randomised clinical trial comparing all commonly used topical treatments exists. The aim of
P C M van de Kerkhof et al.
Dermatology (Basel, Switzerland), 210(4), 294-299 (2005-06-09)
A two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) has been evaluated in a large clinical trial programme, providing a wealth of data on the treatment of psoriasis vulgaris. To determine the effectiveness of the two-compound product in patients with
Paul L McCormack
American journal of clinical dermatology, 12(6), 421-424 (2011-10-05)
Calcipotriene (calcipotriol)/betamethasone dipropionate (calcipotriene 50 μg/g and betamethasone 0.5 mg/g) is a fixed-dose combination of a vitamin D3 analog and a corticosteroid indicated for the once-daily, topical treatment of psoriasis vulgaris of the trunk, limbs, and scalp in adults. Both
A Charakida et al.
Expert opinion on pharmacotherapy, 7(5), 597-606 (2006-03-24)
The two-compound product calcipotriol/betamethasone dipropionate is arising as a first-line treatment for mild-to-moderate plaque psoriasis. Its beneficial action is attributed to the synergistic effect of its components on keratinocyte proliferation and differentiation, and on inflammation. The good tolerability of the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service